CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis

Table 2 Changes in disease activity and the proportion of monocyte subsets in patients with rheumatoid arthritis (n = 35) at baseline and following 12 weeks of methotrexate treatment

	Baseline	12 weeks	p value
Disease activity parameters
DAS28-ESR	4.83 ± 0.91	3.53 ± 1.25	<0.001
SDAI	18.99 ± 9.87	10.24 ± 7.77	<0.001
CDAI	18.35 ± 9.03	9.84 ± 7.55	<0.001
ESR	35.7 ± 20.0	27.2 ± 23.4	0.0040
CRP	0.64 ± 0.59	0.35 ± 0.59	0.031
Monocyte subsets
CD14^brightCD16- monocytes (%)	72.16 ± 9.87	77.57 ± 9.36	0.0042
CD14^brightCD16+ monocytes (%)	13.96 ± 7.02	10.89 ± 7.25	0.0019
CD14^dimCD16+ monocytes (%)	8.14 ± 4.84	6.41 ± 4.20	0.0619

Statistical analysis, Wilcoxon rank sum test. DAS-28 disease activity score in 28-joint count, SDAI simplified disease activity index, CDAI clinical disease activity index, ESR erythrocyte sedimentation rate, CRP C-reactive protein.

ISSN: 1478-6362